GLOBAL-WEALTH-CONFERENCE
9.5.2024 14:23:33 CEST | Business Wire | Press release
The Sovereign Wealth Fund Institute (SWFI) is proud to announce the return of the Global Wealth Conference (GWC) to London for its second consecutive year from May 28-30, 2024. Building upon the resounding success of the inaugural event, GWC 2024 will once again bring together a distinguished array of industry leaders to share their expertise across various domains.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509188124/en/
London Set to Host Second Annual Global Wealth Conference, Driving Positive Change (Photo: AETOSWire)
"Our inaugural event in London was a triumph, and we are thrilled to return for a second year," said Lakshmi Narayanan, Chairman of SWFI. "The Global Wealth Conference reaffirms our collective commitment as custodians of global prosperity, and we eagerly anticipate the meaningful conversations and collaborations that will emerge from this gathering."
This year's conference will revolve around the theme of Sustainability, Allocation, and Innovation, reflecting a steadfast commitment to tackling critical global challenges while driving cutting-edge advancements in diverse sectors.
The Global Wealth Conference 2024 is an invitation-only event, with no tickets or passes available for sale. To date, over 4,000 applications for invitations have been received, with a final guest list of 450 attendees to be announced in the coming weeks.
The event will feature a lineup of esteemed speakers, including: Ruslan Alikhanov, Chief Executive Officer, Azerbaijan Investment Holding; Gunther Beger, Managing Director, SDG Innovation and Economic Transformation, United Nations Industrial Development Organization; Bella Landymore, Policy and Strategy Director, Impact Investing Institute; Dr. Bridget Kustin, Senior Research Fellow, Saïd Business School, University of Oxford; Anthony H. Yadgaroff, Chair of Trustees, Investment Managers' Charitable Trust; James S. Rosebush, Former Deputy Assistant to the President of the United States, The White House; Kashif Khalid, Managing Director - Middle East & Africa, SimCorp; Matt Scott, Executive Director, UK Centre for Greening Finance & Investment; Michael Sheren, Fellow, Cambridge Institute for Sustainability Leadership among others.
The three-day event will be spread across six iconic venues in London, including the House of Commons, the Great Hall of Guildhall, the London Stock Exchange, and several historic Livery Halls. Attendees can expect an agenda packed with insightful panel discussions, keynote speeches, closed private dinners, round table discussions, traditional entertainment, and networking opportunities. The conference will attract a diverse range of participants, including representatives from sovereign wealth funds, pension funds, asset owners, family offices, and asset managers from around the world.
Please visit https://gwc.events/london2024/
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509188124/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
